Legacy AI grade · Sources dated 2026-06-09. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow
Bifidobacterium animalis subsp. lactis BB-12 for Oral Health
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Bifidobacterium animalis subsp. lactis BB-12 in Oral Health grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
BB-12 does not have strain-specific meta-analytic support for oral health. The three cited meta-analyses pool multiple probiotic strains and cannot attribute benefit to BB-12 alone.
Direct BB-12 RCTs (PMID 23571819, 22327347) address caries prevention in children, not the gingivitis/periodontitis scope implied by multi-strain MA titles.
Tier C reflects non-attributable, multi-strain evidence. Do not extrapolate genus-level probiotic meta-analyses to BB-12 specifically.
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
63%
Broadly consistent
Evidence level
E3
PMIDs 35607893, 26965080, 40186219 pool multiple strains not BB-12 alone
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.502
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 1 positive)，下層 RCT 不能推翻
- apply_hec_override — HEC-1 高階證據 negative — 強制由 C 改為 D
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Efficacy of probiotics against dental caries in children: a systematic review and meta-analysis
Finding: Pooled across 43 RCTs, probiotics modestly reduced cavitated (SMD -0.32, 95% CI -0.50 to -0.14, p=0.0004) and noncavitated (SMD -0.18, 95% CI -0.30 to -0.06, p=0.002) lesions and lowered salivary S. mutans (SMD -1.17, 95% CI -1.85 to -0.50, p=0.0007), but the trials pooled all probiotic genera (mostly Lactobacillus) rather than BB-12 specifically.
View on PubMed Probiotics for managing caries and periodontitis: Systematic review and meta-analysis
Finding: Across 50 studies (3247 participants; 12 used bifidobacteria), probiotics did NOT significantly reduce caries incidence (OR 0.60, 95% CI 0.35 to 1.04) or caries experience (SMD -0.26, 95% CI -0.55 to 0.03), but did reduce bleeding-on-probing (SMD -1.15, 95% CI -1.68 to -0.62) and probing-pocket depth (SMD -0.86, 95% CI -1.55 to -0.17).
View on PubMed Clinical effects of probiotics on the treatment of gingivitis and periodontitis: a systematic review and meta-analysis
Finding: Across 24 RCTs (951 participants), adjunctive probiotics lowered plaque index (95% CI -0.54 to -0.15, p=0.001) and bleeding on probing (95% CI -0.58 to -0.05, p=0.021) in periodontitis, but for gingivitis the reductions in plaque and bleeding were non-significant; the two Bifidobacterium animalis subsp. lactis arms used strain HN019 (not BB-12).
View on PubMed Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults
Finding: The LGG+BB-12 lozenge (test n=29 vs control n=31) significantly reduced plaque index and gingival index (both p<0.05) with no change in controls, but produced no significant reduction in salivary mutans streptococci; because BB-12 was co-administered with LGG, the benefit cannot be attributed to BB-12 alone.
View on PubMed Administration of Bifidobacterium animalis subsp. lactis BB-12 in early childhood: a post-trial effect on caries occurrence at four years of age
Finding: Infant BB-12 supplementation produced no difference in enamel caries (p=0.268) or dentinal caries (p=0.201) at age 4, with the authors concluding BB-12 in infancy 'does not seem to increase or decrease the occurrence of caries by 4 years of age.'
View on PubMed Bifidobacterium animalis subsp. lactis BB-12 administration in early childhood: a randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic
Finding: At age 2, mutans streptococci colonization was low and statistically differed across arms (BB-12 6% vs xylitol 31% vs sorbitol 10%, p<0.05), but BB-12 did not establish lasting oral colonization (absent in all 2-year samples), so any signal is on a surrogate marker, not a clinical caries endpoint.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). source↗
L4b EU EFSA
Cautious
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… source↗
L5a NIH Office of Dietary Supplements
Supportive
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … source↗
L5c Cleveland Clinic
Supportive
Many probiotic products are formulated with beneficial bacteria and yeasts for the purpose of preventing or recovering from bacterial or yeast infections in your different body parts, including: ... Cavities and gum disease. source↗